Peptide Studies Have a Population Problem: Who Was Actually Studied?

For most of modern drug development, “the average patient” in a clinical trial was, quietly and by default, a man. That’s not a conspiracy theory. It’s a documented pattern in how pharmacokinetic research got built, and it has a measurable consequence that’s still showing up in adverse event data today.

The finding

A 2020 analysis published in Biology of Sex Differences reviewed the pharmacokinetic literature across 86 FDA-approved drugs, specifically looking at whether men and women given the identical dose ended up with different blood concentrations and different elimination times (Zucker and Prendergast). Of those 86 drugs, 76 showed women reaching higher blood concentrations than men at the same dose, or clearing the drug more slowly, or both.

The part that matters clinically: 96% of drugs where women showed higher pharmacokinetic values were also drugs where women experienced adverse drug reactions more often than men. That’s not a loose correlation. It’s a strong, specific pattern, higher exposure at an identical dose predicting more side effects, and it held even after accounting for body weight differences between men and women.

Why this happened

Women were excluded from most early-phase clinical drug trials for decades, based partly on concerns that hormonal fluctuations across the menstrual cycle would complicate the data, concerns that were never rigorously tested before becoming standard practice. The result was a drug development pipeline where dosing was calibrated almost entirely on male physiology, then applied to everyone. The NIH didn’t mandate that federally funded research include both sexes as a study variable until 2016. That’s a recent policy shift relative to how long most currently prescribed drugs have been on the market.

What this doesn’t mean

This isn’t evidence that women are simply more sensitive to medication in some vague sense, and it isn’t a reason to distrust pharmaceutical dosing categorically. It’s a specific, measurable finding about pharmacokinetics, how a drug moves through and is cleared from the body, and it points to an evidence gap rather than a conspiracy: accessible, sex-stratified pharmacokinetic data is still only available for a small fraction of drugs currently in use, according to the same analysis. Where the data exists, the pattern is consistent. For most drugs, it simply hasn’t been collected or published in a form researchers can analyze at all.

Why this matters for how research gets read

Any time a drug’s dosing, safety profile, or clinical trial results get discussed without noting who was actually enrolled and whether the sample was analyzed by sex, there’s a real possibility the reported average is describing one population more accurately than another. That’s true of pharmaceutical drugs, and there’s no reason to think it becomes less true for peptides and compounds still working through earlier stages of research. Reading past the topline number to ask who was actually studied is a genuinely useful habit, not just for this specific finding, but for how to read clinical research generally.

References

Zucker, Irving, and Brian J. Prendergast. “Sex Differences in Pharmacokinetics Predict Adverse Drug Reactions in Women.” Biology of Sex Differences, vol. 11, 2020, article 32.